Manasa Kesari Lakshmi, Pujitha Sravya, Sethi Aaftaab, Mohammed Arifuddin, Alvala Mallika, Angeli Andrea, Supuran Claudiu T
Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad-500 037, India.
Department of Chemistry, Anwarul Uloom College, 11-3-918, New Malleypally, Hyderabad-500001, T. S., India (Present Address).
Metabolites. 2020 Mar 31;10(4):136. doi: 10.3390/metabo10040136.
A novel series of imidazo[2,1-]thiazole-sulfonyl piperazine conjugates (9aa-ee) has been synthesized and evaluated for carbonic anhydrase (CA, EC 4.2.1.1) inhibitory potency against four isoforms: The cytosolic isozyme hCA I, II and trans-membrane tumor-associated isoform hCA IX and hCA XII, taking acetazolamide (AAZ) as standard drug, using a stopped flow CO hydrase assay. The results revealed that most of the compounds showed selective activity against hCA II whereas none of them were active against hCA I, IX, XII (K > 100 µM). The physiologically dominant cytosolic isoform hCA II was inhibited by these molecules with inhibition constants in the range of 57.7-98.2 µM. This new derivative, thus, selectively inhibits hCA II over the hCA I, IX, XII isoforms, which may be used for further understanding the physiological roles of some of these isoforms in various pathologies.
已合成了一系列新型的咪唑并[2,1 - ]噻唑 - 磺酰基哌嗪共轭物(9aa - ee),并针对四种同工型评估了其对碳酸酐酶(CA,EC 4.2.1.1)的抑制效力:胞质同工酶hCA I、II以及跨膜肿瘤相关同工型hCA IX和hCA XII,以乙酰唑胺(AAZ)作为标准药物,采用停流CO水合酶测定法。结果表明,大多数化合物对hCA II表现出选择性活性,而它们对hCA I、IX、XII均无活性(K>100 μM)。这些分子抑制了生理上占主导地位的胞质同工型hCA II,抑制常数范围为57.7 - 98.2 μM。因此,这种新衍生物对hCA I、IX、XII同工型具有选择性抑制hCA II的作用,这可用于进一步了解这些同工型在各种病理中的一些生理作用。